SCHEMBL3524770

SCHEMBL3524770

COC(=O)OC1(O)c2ccccc2-c2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
ITGA4 P13612 1/20 0.46
THRB P10828 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
PDK2 Q15119 17/20 0.43
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6154693 0.81 MAPT (0.46) ALDH1A1MAPTITGA4THRBTDP1
SCHEMBL27603459 0.81 THRB (0.48) ALDH1A1MAPTITGA4THRBTDP1
SCHEMBL5731610 0.81 P2RX4 (0.42) ALDH1A1MAPTITGA4
SCHEMBL987799 0.79 THRB (0.55) ALDH1A1MAPTITGA4THRBTDP1
SCHEMBL996855 0.75 THRB (0.43) ALDH1A1MAPTITGA4THRBTDP1
SCHEMBL996856 0.74 THRB (0.42) ALDH1A1MAPTITGA4THRBTDP1
SCHEMBL29663083 0.73 THRB (0.59) ALDH1A1MAPTITGA4THRBTDP1
SCHEMBL3245527 0.73 THRB (0.59) ALDH1A1MAPTITGA4THRBTDP1
SCHEMBL16137604 0.73 THRB (0.44) ALDH1A1MAPTITGA4THRBTDP1
SCHEMBL18894103 0.72 MAPT (0.38) ALDH1A1MAPTITGA4THRBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10688522-B2 Method of coating a lens and lens support TRANSITIONS OPTICAL, INC. (US) 2020-06-23 US disclosed
US-10619098-B2 Ultraviolet light absorbers TRANSITIONS OPTICAL, INC. (US) 2020-04-14 US disclosed
US-10444537-B2 Optical article having a photoluminescent mark TRANSITIONS OPTICAL, INC. (US) 2019-10-15 US disclosed
US-10281628-B2 Method of preparing a photochromic optical article using an organic solvent pretreatment and photochromic coating TRANSITIONS OPTICAL, INC. (US) 2019-05-07 US disclosed
EP-3248054-B1 OPTICAL ARTICLE HAVING A PHOTOLUMINESCENT MARK TRANSITIONS OPTICAL INC (US) 2018-12-12 EP disclosed
EP-3201292-B1 ULTRAVIOLET LIGHT ABSORBERS TRANSITIONS OPTICAL INC (US) 2018-08-01 EP disclosed
EP-3071401-B9 METHOD OF FORMING A PHOTOCHROMIC SEGMENTED MULTIFOCAL LENS TRANSITIONS OPTICAL INC (US) 2018-03-14 EP disclosed
US-20180024377-A1 Optical Article Having a Photoluminescent Mark TRANSITIONS OPTICAL, INC. 2018-01-25 US disclosed
US-20170275534-A1 ULTRAVIOLET LIGHT ABSORBERS TRANSITIONS OPTICAL, INC. 2017-09-28 US disclosed
EP-3071401-B1 METHOD OF FORMING A PHOTOCHROMIC SEGMENTED MULTIFOCAL LENS TRANSITIONS OPTICAL INC (US) 2017-09-20 EP disclosed
EP-1196466-B1 POLYMERIZABLE COMPOSITION OF ALIPHATIC POLYOL (ALLYL CARBONATE) PPG IND OHIO INC (US) 2005-01-26 EP disclosed
EP-1497288-A1 NOVEL ESTER HYDROXY-SUBSTITUTED NITROGEN HETEROCYCLES AS ANTAGONISTS OF THE MUSCARINIC M3 RECEPTOR, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2005-01-19 EP disclosed
EP-1494680-A1 USE OF CARBON-2-MODIFIED-VITAMIN D ANALOGS TO INDUCE THE FORMATION OF NEW BONE WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2005-01-12 EP disclosed
EP-1472251-A1 NOVEL FLUORENE CARBOXYLIC ACID ESTERS, METHODS FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS PHARMACEUTICALS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-11-03 EP disclosed
WO-2003087096-A1 NOVEL ESTER HYDROXY-SUBSTITUTED NITROGEN HETEROCYCLES AS ANTAGONISTS OF THE MUSCARINIC M3 RECEPTOR, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-10-23 WO disclosed
WO-2003082300-A1 USE OF CARBON-2-MODIFIED-VITAMIN D ANALOGS TO INDUCE THE FORMATION OF NEW BONE WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2003-10-09 WO disclosed
WO-2003064419-A1 NOVEL FLUORENE CARBOXYLIC ACID ESTERS, METHODS FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS PHARMACEUTICALS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-08-07 WO disclosed
EP-1268416-A1 2-ALKYLIDENE-19-NOR-VITAMIN D COMPOUNDS AND THEIR THERAPEUTIC USES WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2003-01-02 EP disclosed
US-6316570-B1 FOR PRODUCING POLYMERIZATES HAVING CLARITY, GOOD FLEXIBILITY, ABRASION RESISTANCE WHICH ARE USED IN PREPARATION OF MOLDED ARTICLES SUCH AS LENSES PPG INDUSTRIES OHIO, INC. 2001-11-13 US disclosed
WO-2001074766-A1 2-ALKYLIDENE-19-NOR-VITAMIN D COMPOUNDS AND THEIR THERAPEUTIC USES WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10619098-B2 Ultraviolet light absorbers ERCC1, MCM4, ERCC4 ALDH1A1 590/4885MAPT 80/4885ITGA4 2332/4885
US-20170275534-A1 ULTRAVIOLET LIGHT ABSORBERS MCM4, ERCC1, ERCC4 ALDH1A1 392/4885MAPT 85/4885ITGA4 2467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.